Modeling of κ-opioid receptor/agonists interactions using pharmacophore-based and docking simulations

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2124-2134

  Lavecchia, Antonio ^a   Greco, Giovanni ^a   Novellino, Ettore ^a   Vittorio, Franco ^b   Ronsisvalle, Giuseppe ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BENZOMORPHAN DERIVATIVE; KAPPA OPIATE RECEPTOR AGONIST;

ANALGESIC ACTIVITY; ANIMAL TISSUE; ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYDROGEN BOND; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; COMPUTER SIMULATION; CYCLAZOCINE; MODELS, CHEMICAL; MOLECULAR CONFORMATION; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034214399     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991161k     Document Type: Article

References (69)

1. Simon, E. J.; Gioannini, T. L. Opioid Receptor Multiplicity: Isolation, Purification and Chemical Characterization of Binding Sites. In Handbook of Experimental Pharmacology, 104/1; Herz A. Ed.; Springer-Verlag: Berlin, 1993; pp 3-26.
2. Reisine, T.; Bell, G. I. Molecular Biology of Opioid Receptors. Trends Neurosci. 1993, 16, 506-510.
3. Millan, M. J. κ-Opioid Receptor and Analgesia. Trends Pharmacol. Sci. 1990, 11, 70-76.
4. Jaffe, H. I.; Martin, W. R. Opioid Analgesics and Antagonists. In The Pharmacologic Basis of Therapeutics, 8th ed.; Goodman, L. S., Gilman, A. G., Rall, T. W., Nies, A. S., Taylor, P., Eds.; Pergamon Press: New York, 1990; pp 485-521.
5. Ronsisvalle, G.; Pasquinucci, L.; Pappalardo, M. S.; Vittorio, F.; Fronza, G.; Romagnoli, C.; Pistacchio, E.; Spampinato, S.; Ferri, S. Non-Peptide Ligands for Opioid Receptors. Design of κ-Specific Agonists. J. Med. Chem. 1993, 36, 1860-1865.
6. Szmuszkovicz, J.; Von Voigtlander, P. F. Benzeneacetamide Amines: Structurally Novel non-μ-Opioids. J. Med. Chem. 1982, 25, 1125-1126.
7. Higginbottom, M.; Nolan, W.; O'Toole, J.; Ratcliffe, G. S.; Rees, D.; Roberts, E. The Design and Synthesis of Kappa Opioid Ligands Based on a Binding Model for Kappa Agonists. Bioorg. Med. Chem. Lett. 1993, 5, 841-846.
8. Froimowitz, M.; DiMeglio, C. M.; Makryannis, A. Conformational Preferences of the κ-Selective Opioid Agonist U-50, 488. A Combined Molecular Mechanics and Nuclear Magnetic Resonance Study. J. Med. Chem. 1992, 35, 3094-3102.
9. Brandt, W.; Drosihn, S.; Haurand, M.; Hozgrabe, U.; Nachtsheim, C. Search for the Pharmacophore in Kappa-Agonistic Diazabicyclo[3.3.1]nonan-9-one-1,5-diesters and Arylacetamides. Arch. Pharm. Pharm. Med. Chem. 1996, 329, 311-323.
10. Subramanian, G.; Paterlini, M. G.; Larson, D.; Portoghese, P. S.; Ferguson, D. Conformational Analysis and Automated Receptor Docking of Selective Arylacetamide-Based κ-Opioid Agonists. J. Med. Chem. 1998, 41, 4777-4789.
11. Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid Receptor Three-Dimensional Structures from Distance Geometry Calculations with Hydrogen Bonding Constraints. Biophys. J. 1998, 75, 612-634.
12. Cappelli, A.; Anzini, M.; Vomero, S.; Menziani, M. C.; De Benedetti, P. G.; Sbacchi, M.; Clarke, G. D.; Mennuni, L. Synthesis, Biological Evaluation, and Quantitative Receptor Docking Simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as Novel Tifluadom-like Ligands with High Affinity and Selectivity for κ-Opioid Receptors. J. Med. Chem. 1996, 39, 860-872.
13. Metzger, T. G.; Paterlini, M. G.; Portoghese, P. S., Ferguson, D. M. Application of the Message-Address Concept of the Docking of Naltrexone and Selective Naltrexone-derived Opioid Antagonists into Opioid Receptor Models. Neurochem Res. 1996, 21, 1287-1294.
14. Cheng, C.-Y.; Lu, H.-Y.; Lee, F.-M.; Tam, S. W. J. Synthesis of (1′,2′-trans)-3-phenyl-1-[2′-(N-pyrrolidinyl)cyclohexyl] pyrrolid-2-ones as κ-Selective Opiates. J. Pharm. Sci. 1990, 79, 758-762.
15. Drug Data Rep. 1993, 015(09).
16. Vecchietti, V.; Clarke, G. D.; Colle, R.; Dondio, G.; Giardina, G.; Petrone, G.; Sbacchi, M. Substituted 1-(aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinolines: a Novel Class of Very Potent Antinociceptive Agents with Varying Degrees of Selectivity for κ and μ Opioid Receptors. J. Med. Chem. 1992, 35, 2970-2978.
17. Fuibayashi, K.; Sakamoto, K.; Watanabe, M.; Iizuka, Y. Pharmacological Properties of R-84760, a Novel κ-Opioid Receptor Agonist. Eur. J. Pharmacol. 1994, 261, 133-140.
18. Rajagopalan, P.; Scribner, R. M.; Pennev, P.; Mattei, P. L.; Kezar, H. S.; Cheng, C. Y.; Cheeseman, R. S.; Ganti, V. R.; Johnson, A. L.; Wuonola, M. A.; Schmidt, W. K.; Tam, S. W.; Steinfels, G. F.; Cook, L. Dup-747: SAR Study. Bioorg. Med. Chem. Lett. 1992, 2, 721-726.
19. Sabin, V.; Horwell, D. C.; McKnight, A. T.; Broqua, P. trans N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]cycloprop-2-ene-1-carboxamides: Novel Lipophilic Kappa Opioid Agonists. Bioorg. Med. Chem. Lett. 1997, 7, 291-296.
20. Fujimoto, R. A.; Boxer, J.; Jackson, R. H.; Simke, R. F. N.; Snowhill, E. W.; Barbaz, B. J.; Williams, M.; Sills, M. A. J. Med. Chem. 1989, 32, 1259-1265.
21. Halfpenny, P. R.; Horwell, D. C.; Hughes, J.; Hunter, J. C.; Rees, D. C. Higly Selective κ-Opioid Analgesics. 3. Synthesis and Structure Activity Relationships of Novel N-[2-(1-pyrrolidinyl)-4-or -5-substituted-cyclohexyl]arylacetamide Derivatives. J. Med. Chem. 1990, 33, 286-291.
22. Hayes, A. G.; Birch, P. J.; Hayward, N. J.; Sheehan M. J.; Rogers, H.; Tyers, M. B.; Judd, D. B.; Scopes, D. I. C.; Naylor, A. A Series of Novel, Highly Potent and Selective Agonists for the κ-Opioid Receptor. Br. J. Pharmacol. 1990, 101, 944-948.
23. Vecchietti, V.; Giordani, A.; Giardina, G.; Colle, R.; Clarke, G. D. (2S)-1-1(arylacetyl)-2-(aminomethyl)piperidine Derivatives: Novel, Highly Selective κ-Opioid Analgesics. J. Med. Chem. 1991, 34, 397-403.
24. Giardina, G.; Clarke, G. D.; Dondio, G.; Petrone, G.; Sbacchi, M.; Vecchietti, V. Selective κ-Opioid Agonists: Synthesis and Structure Activity Relationships of Piperidines Incorporating an Oxo-Containing Acyl Group. J. Med. Chem. 1994, 37, 3482-3491.
25. Vecchietti, V.; Clarke, G. D.; Colle, R.; Giardina, G.; Petrone, G.; Sbacchi, M. (1S)-1-(aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinoline and heterocyclic-condensed tetrahydropyridine Derivatives: Members of a Novel Class of Very Potent κ-Opioid Analgesics. J. Med. Chem. 1991, 34, 2624-2633.
26. Clark, C. R.; Halfpenny, P. R.; Hill, R. G.; Horwell, D. C.; Hughes, J.; Jarvis, T. C.; Rees, D. C.; Schofield, D. Highly Selective κ-Opioid Analgesics. Synthesis and Structure Activity Relationships of Novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide Derivatives. J. Med. Chem. 1988, 31, 831-836.
27. 3H]U-69593, a Highly Selective Ligand for the Opioid κ-Receptor. Eur. J. Pharmacol. 1985, 109, 281-284.
28. Hunter, J. C.; Leighton, G. E.; Meecham, K. G.; Boyle, S. J.; Horwell, D. C.; Rees, D. C.; Huges, J. CI-977, a Novel and Selective Agonist for the κ-Opioid Receptor. Br. J. Pharmacol. 1990, 101, 183-189.
29. Costello G. F.; Main, B. G.; Barlow, J. J.; Carroll, J. A.; Shaw, J. S.; A Novel Series of Potent and Selective Agonists at the Opioid κ-Receptor. Eur J. Pharmacol. 1988, 151, 475-478.
30. Barlow, J. J.; Blackburn, T. P.; Costello, G. F.; James, R.; Le Count, D. J.; Main, B. G.; Pearce, R. J.; Russell, K.; Shaw, J. S. Structure-Activity Studies Related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl] acetamides: a Novel Series of Potent and Selective κ-Opioid Agonists. J. Med. Chem. 1991, 34, 3149-3158.
31. Naylor, A.; Judd, D. B.; Lloyd, J. E.; Scopes, D. I. C.; Hayes, A. G.; Birch, P. J. A Potent New Class of κ-Opioid Agonists: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. J. Med. Chem. 1993, 36, 2075-2083.
32. Kong, H.; Raynor, K.; Reisine, T. Amino acids in the Cloned Kappa Receptor that are Necessary for the High Affinity Agonist Binding but not Antagonist Binding. Reg. Pept. 1994, 54, 155-156.
33. 21 to produce a 15-fold drop of affinity. Such a structural modification does not alter the conformational proprieties and implies only slight differences in the steric bulk of the (thio)amidic moieties. Considering that the thioamidic sulfur is still a hydrogen-bond acceptor, although less good than the amidic oxygen [Raevsky et al. Quantum Struct.-Act-Relat. 1992, 11, 49-63.], the above-quoted 15-fold difference in binding affinity seems consistent with the hypothesis of a hydrogen-bond interaction involving the thioamidic carbonyl group at the binding site.
34. de Costa, B. R.; Bowen, W. D.; Hellewell, S. B.; George, C.; Rothman, R. B.; Reid, A. A.; Walker, J. M.; Jacobson, A. E.; Rice, K. C. Alterations in the Stereochemistry of the κ-Selective Opioid Agonist U-50,488 Results in High-Affinity σ Ligands. J. Med. Chem. 1989, 32, 1996-2002.
35. de Costa, B. R.; Radesca, L.; Paolo, L. D.; Bowen, W. D. Synthesis, Characterization, and Biological Evaluation of a Novel Class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: Structural Requirements and Binding Affinity at the σ Receptor. J. Med. Chem. 1992, 35, 38-47.
36. Radesca, L.; Bowen, W. D.; Paolo, L. D.; de Costa, B. R. Synthesis and Receptor Binding of Enantiomeric N-substituted cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamines as High-Affinity σ Receptor Ligands. J. Med. Chem. 1991, 34, 3058-3065.
37. 2 Receptor Antagonists. Pharm. Pharmacol. Lett. 1992, 1, 89-93.
38. Martin, Y. C. Pharmacophore Mapping. In Designing Bioactive Molecules Three-Dimenaional Techniques and Applications; Martin, Y. C., Willett, P. Eds.; American Chemical Society, Washington, DC, 1998; pp 121-148.
39. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, A. A Fast New Approach to Pharmacophore Mapping and its Application to Dopaminergic and Benzodiazepine Agonists. J. Comput.-Aided Mol. Design 1993, 7, 83-102.
40. Vinter, J. G.; Davis, A.; Saunders: M. R. Strategic Approaches to Drug Design. 1. An Integrated Software Framework for Molecular Modelling. J. Comput.-Aided Mol. Design 1987, 1, 31-55.
41. Marshall, G. R.; Barry, C. D.; Bosshard, R. A.; Dammkoehler, R. A.; Dunn, D. A. The Conformational Parameter in Drug Design: the Active Analogue Approach. In Computer-Assisted Drug Design; Olson, E. C., Christoffersen, R. E., Eds.; ACS Symp., Series 112, America Chemical Society, Washington, DC, 1979; pp 205-226.
42. Wermuth, C. G.; Langer, T. Pharmacophore Identification. In 3D QSAR in Drug Design. Theory Methods and Applications; Kubinyi, H., Ed., ESCOM, Leiden, 1993; pp 117-136.
43. Allen, F. H.; Bellard, S.; Brice, M. D.; Cartwright, B. A.; Doubleday: A.; Higgs, H.; Hummelink, T.; Hummelink-Peters, B. G.; Kennard, O.; Motherwell, W. D. S.; Rodgers, J. R.; Watson, D. G. The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information. Acta Crystallogr. 1979, B35, 2331-2339.
44. Metzger, T. G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson, D. M. An Analysis of the Conserved Residues between Halobacterial Retinal Proteins and G-Protein Coupled Receptors: Implications for GPCR Modeling. J. Chem. Inf. Comput. Sci. 1996, 36, 857-861.
45. Meng, E. C.; Shoichet, B. K.; Kuntz, I. D. Automated Docking with Grid-Based Energy Evaluation. J. Comput. Chem. 1992, 13, 505-524.
46. (b) Meng, E. C.; Gschwend, D. A.; Blaney, J. M.; Kuntz, I. D. Orientational Sampling and Rigid-Body Minimization in Molecular Docking. Proteins: Struct., Funct., Genet. 1993, 17, 266-278.
47. Connolly, M.; Gschwend, D. A.; Good, A. C.; Oshiro, C.; Kuntz, I. D. DOCK 3.5, Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, 1995.
48. One of the reviewers observed that fitting the so-called tyramine moiety of MPCB on that of arylacetamides 4 and 6 might have allowed to verify whether these substructures interact in a similar mode with the receptor. Although the tyramine moiety was not considered as a pharmacophore element in our study (it is absent in U-50,488 as well as in many other potent arylacetamides), we attempted to superimpose MPCB on the docked conformation of 6 about the tyramine moiety. However, the resulting orientation of MPCB was characterized by the ammonium N-H vector pointing away from the Asp138 carboxylate oxygens, thus preventing these two functions from establishing the hypothesized salt-bridge. Additionally, the N-side chain of MPCB in each of the conformers 3-8 gave rise to severe steric conflicts within the receptor binding site. For these reasons, this type of fitting was not further considered. Figure 11 (docked conformations of 6 and MPCB obtained using DOCK 3.5) shows that the two tyramine moieties are not coincident in space, although both ammonium groups form a salt-bridge with the Asp138 carboxylate and both phenolic hydroxyls make a hydrogen bond with His291.
49. Uhl, G. R.; Childers, S.; Pasternak, G. An Opiate-Receptor Gene Family Reunion. TINS 1994, 17, 89-93.
50. Surratt, C. K.; Johnson, P. S.; Moriwaki, A.; Seidleck, B. K.; Blaschak, C. J.; Wang, J. B.; Uhl, G. R. μ-Opioid Receptor. Charged Transmembrane Domain Amino Acids are Critical for Agonist Recognition and Intrinsic Activity. J. Biol. Chem. 1994, 269, 20548-20553.
51. th Meeting of the International Narcotics Research Conference (INRC) '96, 1996; poster M30.
52. Barlow, D. J.; Thornton, J. M. Ion-Pairs in Proteins. J. Mol. Biol. 1983, 168, 867-885.
53. (b) Zheng, Y.-J.; Ornstein, R. L. What Happens to Salt Bridges in Nonaqueous Environments: Insights from Quantum Mechanics Calculations. J. Am. Chem. Soc. 1996, 118, 11237-11243 and references therein.
54. Tintelnot, M.; Andrews, P. Geometries of Functional Group Interactive in Enzyme-Ligand Complexes: Guides for Receptor Modelling. J. Comput.-Aided Mol. Design 1989, 3, 67-84.
55. Davis, A. M.; Teague, S. J. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis, Angew. Chem., Int. Ed. 1999, 38, 737-749.
56. Mattos, C.; Ringe, D. Multiple Binding Modes. In 3D QSAR in Drug Design. Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 117-136.
57. Kubinyi, H. Similarity and Dissimilarity: A Medicinal Chemist's View. In 3D QSAR in Drug Design. Ligand-Protein Interactions and Molecular Similarity; Kubinyi, H., Folkers, G., Martin, Y. C., Eds.; KLUWER/ESCOM, vol. 2, 1998; pp 225-252.
58. Ringe, D. Immunosuppression. Binding by Design. Nature 1991, 351, 185.
59. (b) Shoichet, B. K.; Stroud, R. M.; Santi, D. V.; Kuntz, I. D.; Perry, K. M. Stucture-Based Discovery of Inhibitors of Thymidylate Synthase. Science 1993, 259, 1445-1450.
60. Rutenber, E.; Fauman, E. B.; Keenan R. J.; Fong, S.; Furth, P. S.; Ortiz de Montellano, P. R.; Meng, E.; Kunz, I. D.; DeCamp, D. L.; Salto, R.; Rosè, J. R.; Craik, C.; Stroud, R. M. Structure of a Non-Peptide Inhibitor Complexed with HIV-1 Protease. Developing a Cycle of Structure-Based Drug Design. J. Biol. Chem. 1993, 268, 15343-15346.
61. Sybyl Molecular Modelling System (version 6.2), Tripos Assoc., St. Louis, MO.
62. A common practice when generating potentially bioactive conformations is to neglect the electrostatic contribution, if strong electrostatic interactions are expected to occur intramolecularly (Höltje, H.-D.; Folkers, G. Computational Tools for Geometry Optimitation. In Molecular Modeling Basic Principles and Applications; Mannhold, R.; Kubinyi, H.; Timmerman, H., Eds.; VCH: New York, 1996; p 18).
63. Head, J.; Zerner, M. C. A Broyden-Fletcher-Goldfarb-Shanno Optimization Procedure for Molecular Geometries. Chem. Phys. Lett. 1985, 122, 264-274.
64. Cieplak, P.; Cornell, W. D.; Bayly, C.; Kollman, P. A. Application of the Multimolecule and Multiconformational RESP Methodology to Biopolymers: Charge Derivation for DNA, RNA, and Proteins. J. Comput. Chem. 1995, 16, 1357-1377.
65. Foresman, J. B.; Frisch E. In Exploring Chemistry with Electronic Structure Methods, 2nd ed.; Gaussian, Inc.: Pittsburgh, 1996.
66. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E., III.; Debolt, S.; Ferguson, D. M.; Seibel, G. L.; Kollman, P. A. AMBER, a Package of Computer Programs for Applying Molecular Mechanics, Normal-Mode Analysis, Molecular Dynamics and Free Energy Calculations to Simulate the Structural and Energetic Properties of Molecules. Comput. Phys. Commun. 1995, 91, 1-41.
67. (b) Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E., III.; Ferguson, D. M.; Seibel, G.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. AMBER 4.1, Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, 1995.
68. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
69. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular Dynamics with Coupling to an External Bath, J. Chem. Phys. 1984, 81, 3684-3690.